MANE Veradermics, Inc
Pharmaceutical Preparations · NYSE · SEC CIK 1827635 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-11.7%
ROA-11.6%
ROIC (approx.)-13.2%
Asset turnover—
Leverage & solvency
Liabilities / assets1.3%
Debt / equity0.00x
Current ratio77.68x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.88x
Accruals ratio-1.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | — | — | — | — | — | — | — |
| R&D expense | $16.07M | $18.61M | $20.93M | $18.19M | $18.10M | $14.33M | $11.45M |
| SG&A expense | $12.70M | $10.95M | $8.94M | $4.82M | $2.25M | $1.74M | $1.47M |
| Operating income | -$28.78M | -$29.55M | -$29.86M | -$23.01M | -$20.35M | -$16.07M | -$12.91M |
| Pretax income | -$21.00M | -$23.50M | -$27.23M | -$21.85M | -$20.10M | -$15.64M | -$12.40M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$21.00M | -$23.50M | -$27.23M | -$21.85M | -$20.10M | -$15.64M | -$12.40M |
| EPS (basic) | -0.50 | -0.58 | -1.32 | — | -30.15 | -24.19 | -19.79 |
| EPS (diluted) | -0.50 | -0.58 | -1.32 | — | -30.15 | -24.19 | -19.79 |
| Weighted avg. shares (diluted) | 42.12M | 40.44M | 22.70M | — | 748,485 | 744,641 | 736,933 |
| Balance sheet | |||||||
| Cash & equivalents | $132.16M | $319.33M | $168.41M | $21.77M | $5.66M | $8.60M | $32.44M |
| Short-term investments | $666.19M | $500.56M | $222.38M | $120.10M | — | — | — |
| Current assets | $805.78M | $824.75M | $397.07M | $152.49M | — | — | — |
| PP&E, net | $386,000 | $41,000 | $21,000 | $22,000 | — | — | — |
| Total assets | $807.22M | $825.74M | $397.36M | $152.62M | — | — | — |
| Current liabilities | $10.37M | $11.69M | $6.72M | $9.15M | — | — | — |
| Total liabilities | $10.74M | $12.12M | $6.72M | $9.16M | — | — | — |
| Shareholders' equity | $796.47M | $813.61M | $390.64M | -$121.01M | -$96.01M | -$76.07M | -$60.67M |
| Shares outstanding | 42.19M | 41.78M | 37.34M | 749,760 | — | — | — |
| Cash flow statement | |||||||
| Operating cash flow | -$22.95M | -$14.49M | -$21.17M | -$23.63M | -$19.01M | -$15.64M | -$13.32M |
| Capital expenditure | $346,000 | $21,000 | $0 | $5,000 | $0 | $0 | $19,000 |
| Free cash flow | -$23.29M | -$14.51M | -$21.17M | -$23.63M | -$19.01M | -$15.64M | -$13.34M |
| Investing cash flow | -$165.56M | -$277.29M | -$101.30M | -$109.78M | $15.00M | -$8.33M | -$15.75M |
| Financing cash flow | $1.33M | $442.70M | $269.11M | $149.51M | $1.08M | $129,000 | $8.42M |
| Stock-based compensation | $4.09M | $3.52M | $5.26M | $974,000 | $138,000 | $115,000 | $213,000 |
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.